Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

RocketQueen Apr. 15 at 3:37 PM

$IGC once patient enrollment for the CALMA clinical trial is complete, this could really start to take off.

0 · Reply

IGC Apr. 15 at 2:16 PM

$IGC Reaching ~80% patient enrollment, IGC Pharma continues progressing its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease. The study, a randomized, double-blind, placebo-controlled trial, is now entering its final phase of recruitment across its U.S. and Canadian clinical network, with enrollment completion expected in mid-2026. Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-reaches-80-enrollment-123000503.html . . #IGCPharma #AlzheimersResearch #ClinicalTrials #DrugDevelopment #InvestorUpdate

0 · Reply

JrChase Apr. 15 at 9:47 AM

$IGC Target Projection $4.12🎯

0 · Reply

focafoca99 Apr. 14 at 7:36 PM

$IGC Phase 2 CALMA results! https://www.rapidticker.com/news/igc-igc-pharma-reaches-80-enrollment-fd3087

0 · Reply

RocketQueen Apr. 14 at 1:40 PM

$IGC notice that Ascendiant keeps raising their price target. The average for all PTs is now over 4.00 USD.

1 · Reply

David_M_ Apr. 13 at 3:02 PM

$IGC

0 · Reply

macroaxis Apr. 13 at 3:23 AM

$IGC - Implied volatility decreases to 1.32 for India Globalization https://www.macroaxis.com/stock-options/IGC/India-Globalization-Capital?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

luminouslumens Apr. 10 at 7:16 PM

$IGC 🧐

0 · Reply

Vote4Pedro2 Apr. 10 at 5:53 PM

$IGC playing witt

0 · Reply

Scatchtape Apr. 10 at 3:09 PM

$IGC

0 · Reply

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 8, 2026, 12:45 PM EDT - 7 days ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

Apr 7, 2026, 8:00 AM EDT - 8 days ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

Mar 30, 2026, 8:00 AM EDT - 16 days ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

Mar 19, 2026, 9:00 AM EDT - 27 days ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

Mar 18, 2026, 9:00 AM EDT - 4 weeks ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Feb 26, 2026, 8:30 AM EST - 6 weeks ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 7 weeks ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 23, 2026, 8:30 AM EST - 7 weeks ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 17, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 2 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 9, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 2, 2026, 8:30 AM EST - 2 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 2 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 3 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 3 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 3 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 2, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 13, 2025, 9:00 AM EST - 5 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 5 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 5 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 6 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 9 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 10 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 10 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

RocketQueen Apr. 15 at 3:37 PM

$IGC once patient enrollment for the CALMA clinical trial is complete, this could really start to take off.

0 · Reply

IGC Apr. 15 at 2:16 PM

0 · Reply

JrChase Apr. 15 at 9:47 AM

$IGC Target Projection $4.12🎯

0 · Reply

focafoca99 Apr. 14 at 7:36 PM

$IGC Phase 2 CALMA results! https://www.rapidticker.com/news/igc-igc-pharma-reaches-80-enrollment-fd3087

0 · Reply

RocketQueen Apr. 14 at 1:40 PM

$IGC notice that Ascendiant keeps raising their price target. The average for all PTs is now over 4.00 USD.

1 · Reply

David_M_ Apr. 13 at 3:02 PM

$IGC

0 · Reply

macroaxis Apr. 13 at 3:23 AM

$IGC - Implied volatility decreases to 1.32 for India Globalization https://www.macroaxis.com/stock-options/IGC/India-Globalization-Capital?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

luminouslumens Apr. 10 at 7:16 PM

$IGC 🧐

0 · Reply

Vote4Pedro2 Apr. 10 at 5:53 PM

$IGC playing witt

0 · Reply

Scatchtape Apr. 10 at 3:09 PM

$IGC

0 · Reply

mickey1234 Apr. 10 at 1:31 PM

$IGC

0 · Reply

bongha Apr. 10 at 1:05 PM

$IGC

0 · Reply

BladeWarden Apr. 10 at 11:01 AM

$IGC

0 · Reply

Young_Bobby_Axel Apr. 10 at 5:01 AM

$IGC gone

0 · Reply

RocketQueen Apr. 9 at 7:05 PM

$IGC notice how it gets these tiny bumps on news or .30 and then march back to .25. I've watched that happen at least 10 times over the past year or so.

0 · Reply

Young_Bobby_Axel Apr. 9 at 5:40 PM

$IGC slow grind like it

0 · Reply

OffComesTheShirt Apr. 9 at 4:06 PM

$IGC 10% Off Comes The Shirt

0 · Reply

Young_Bobby_Axel Apr. 9 at 4:06 PM

$IGC nice

0 · Reply

twighttrades1 Apr. 9 at 4:00 PM

$IGC - bidding today nicely- healthy buying going on last 2 days…need a release here way low for tool long!

0 · Reply

_AU79_ Apr. 9 at 3:30 PM

$IGC looks ready to blow! just need the right crowd. GL

0 · Reply

Scatchtape Apr. 9 at 2:55 PM

$IGC gooooooooooooooo!!!!

0 · Reply

bongha Apr. 9 at 2:46 PM

$IGC i'm ready

0 · Reply

Market Cap	29.34M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	249,186
Avg Vol	365,452
Day's Range	N/A - N/A
Shares Out	98.80M
Stochastic %K	84%
Beta	0.30
Analysts	Sell
Price Target	$4.12